A Decade of Nintedanib: An Analysis of the FDA Adverse Event Reporting System Database

被引：0
|
作者：
Niranjan, S. [1 ]
Rao, A. [2 ]
Virk, S. T. [1 ]
Sarangdhar, M. [3 ]
机构：
[1] Allegheny Gen Hosp, Internal Med, Pittsburgh, PA USA
[2] Carnegie Mellon Univ, Quantitat Biol & Bioinformat, Pittsburgh, PA USA
[3] Univ Cincinnati, Biomed Informat, Cincinnati, OH USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3746
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Sun, Ximu
    Zhou, Han
    Li, Yanming
    Luo, Yanhui
    Guo, Qixiang
    Sun, Yixin
    Jia, Chenguang
    Wang, Bin
    Qin, Maoquan
    Guo, Peng
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 11 (01)
  • [42] DRUGS ASSOCIATED WITH ADVERSE DRUG EVENTS IN CHILDREN: ANALYSIS OF THE UNITED STATES FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Lee, W. J.
    Schumock, G. T.
    Lee, T. A.
    VALUE IN HEALTH, 2013, 16 (03) : A70 - A70
  • [43] LURASIDONE INDUCED SUICIDAL IDEATION AND HALLUCINATION: DISPROPORTIONALITY ANALYSIS IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Pudi, C.
    Subeesh, V
    Maheswari, E.
    Koonisetty, K. S.
    VALUE IN HEALTH, 2018, 21 : S277 - S277
  • [44] EXPLORING THE INCREASED SERIOUS ADVERSE EVENTS ASSOCIATED WITH INHALED TREPROSTINIL: AN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE ANALYSIS
    Oli, Sharad
    Oli, Shital
    Niraula, Sristee
    Khanal, Resha
    CHEST, 2024, 166 (04) : 3535A - 3535A
  • [45] Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
    Wang, Lingling
    Mao, Zhenyu
    Zheng, Pengdou
    Zi, Guisha
    Zhang, Fengqin
    Zhu, Xiaoyan
    Chen, Lixiang
    Liu, Huiguo
    Zhou, Ling
    Wei, Shuang
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [46] Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
    Lin, Shan
    Luo, Dachen
    Gong, Zonglian
    Zhan, Qingyuan
    FRONTIERS IN MEDICINE, 2024, 11
  • [47] The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database
    Peng, Lufeng
    Li, Xueli
    Li, Junhai
    Liu, Shibin
    Liang, Gang
    PLOS ONE, 2024, 19 (12):
  • [48] Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
    Roberto, Giuseppe
    Piccinni, Carlo
    D'Alessandro, Roberto
    Poluzzi, Elisabetta
    CEPHALALGIA, 2014, 34 (01) : 5 - 13
  • [49] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
    Lao, Dong-Hui
    Chen, Ye
    Fan, Jun
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
  • [50] Improvement in the Analysis of Vaccine Adverse Event Reporting System Database
    Zhao, Lili
    Lee, Sunghun
    Li, Rongxia
    Ong, Edison
    He, Yongqun
    Freed, Gary
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (03): : 303 - 310
12345